Product Images Clopidogrel

This appears to be a chart or graph showing the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke for patients receiving either placebo with aspirin or clopidogrel with aspirin over a follow-up period of 12 months. The chart suggests that the patients who received clopidogrel with aspirin had a lower event rate than those who received only placebo with aspirin. The statistical significance of this difference is indicated to be P=0.00009. Other standard therapies were also used as appropriate.*

This appears to be a table of data regarding the effectiveness of Clopidogrel versus Placebo in reducing the likelihood of certain events, broken down by various characteristics of the study group such as age, gender, race, and concomitant medication usage. The table includes hazard ratios and percentages for each characteristic.*

This text appears to be a comparison between two treatments, Placebo and Clopidogrel, based on the percentage of deaths that occurred before first discharge. It shows that 1845 out of a total of unspecified number of patients who received Placebo died before first discharge, which is 8.1%; while 1726 out of the same unspecified number of patients on Clopidogrel died before first discharge, which is 7.5%. The text also suggests that there was a 7% proportional risk reduction associated with Clopidogrel compared to Placebo, and that this result was statistically significant (p=0.03). The last line appears to indicate the time frame over which the patients were randomized and monitored, with up to 28 days being the maximum.*

This text appears to be presenting data related to the effectiveness of placebo and clopidogrel as treatments for an unspecified medical condition. The data includes the percentage of patients who experienced an event while taking each treatment, as well as information on the risk of death, re-infarction, and stroke. The text also includes a timeline of up to 28 days since randomization.*

This text seems to report statistical information regarding the effects of Clopidogrel compared to Placebo in different categories such as Killip class, previous MI, and infarct location. The numbers reported are in percentages, odds ratios, and confidence intervals, and there is also a trend test reported. The global heterogeneity test results are also shared. The meaning of the reported statistics is unclear without additional context.*

This is a cumulative event rate of fatal or non-fatal vascular events associated with Aspirin and Clopidogrel over 36 months of follow-up. The data is presented in a table format with percentages displayed for different time intervals.*

This is a description of a medicine named Clopidogrel Tablets, USP 75 mg which contains 97.875 mg of clopidogrel bisulfate equivalent to 75 mg clopidogrel base in each tablet. It provides information on usual adult dosage, storage temperature, and dispensation of medication guide by the pharmacist. The medicine comes in a pack of 90 tablets, and is distributed by Wockhardt USA LLC in New Jersey, USA. The size of the tablet is 12.5 mm x 34 mm.*